ClinicalTrials.gg
RecruitingNCT06170840Updated Dec 19, 2023

A Study of QY101 Ointment in Subjects With Plaque Psoriasis

A Phase 2 interventional study of QY101Placebo/QY101 ointment in Psoriasis, sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-19.

Sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled May 2023, registered Dec 2023).
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
93rd of 182
160 · median 171
Started
2023
with 27 others
Phase 2
42 of 206
11 open now
Primary completion
2024-02
later than 2 of 65 live
Registered
124th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 93rd largest by planned enrollment of the 182 interventional ones that give a count, is one of 28 that started in 2023, is one of 42 in phase 2, reaches primary completion later than 2 of the 65 other live ones, and was the 124th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effectiveness of QY101 ointment in adult patients with plaque psoriasis (2-20% BSA).

Read the detailed description

Participants will be stratified and randomly assigned to trial groups two (Test group 1:0.3%; Test group 2:1.0%, 60 patients per group) or placebo group (40 patients) according to the ratio of 3:3:2 and BSA (BSA \< 10% or BSA ≥ 10%) . All groups will be receive with QY101 ointment or placebo, treatment for twice daily (BID) for 12 weeks; All subjects are required to take part in visit at 2, 4, 6, 8 and 12 weeks, they were followed up for efficacy assessment, safety examination and pharmacokinetics samples collection (with week 8 as the primary efficacy endpoint), and safety follow-up was administered 28 ± 7 days after the last dose via telephone .

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able to understand and comply with the test process, voluntarily participate in the test and provide ;
  2. When signing the informed consent, age ≤ 18 years old ≤ 75 years old, gender is not limited;
  3. The patient meets the diagnosis of plaque psoriasis, has a history of plaque psoriasis for ≥ 6 months before randomization, and meets the following conditions:

    1. At baseline, plaque psoriasis covered 2% to 20% of BSA (including both ends) (scalp, palms, and soles were not counted as BSA);
    2. Physician overall assessment (PGA) ≥ 2 at baseline;
  4. Fertile men and women of childbearing age must agree to use reliable from the time they sign an informed consent until six months after the last dose of the drug; Blood pregnancy tests for women of childbearing age must be negative during screening and at baseline.

Exclusion criteria

Exclusion Criteria:

  1. Other types of psoriasis were diagnosed during screening, such as gutting psoriasis, erythrodermic psoriasis, generalized pustular psoriasis, arthropathic psoriasis, drug-induced or drug-aggravated psoriasis;
  2. The presence of other systemic inflammatory diseases and skin lesions (such as eczema), which may affect the evaluation of treatment outcomes;
  3. Subjects who are expected to receive additional local therapy, phototherapy, or other systemic therapy other than medication during the trial;
  4. Taking drugs that can aggravate psoriasis (such as lithium, antimalarial drugs, etc.);
  5. Patients who have failed or are intolerant to previous treatment with Phosphodiesterase-4 (PDE4) inhibitors;
  6. Known to be allergic to the study drug or related (QY101 ointment and excipients: albuvarin, light liquid paraffin, propylene glycol, Carbonic acid, glyceryl behenate, glyceryl monodistearate, hydroxyphenyl butyl, propyl gallate and disodium edetate), or have a history of angioedema or allergy to topical drugs;
  7. receive drugs, supplements, and other treatments prescribed in this trial that may affect the course of psoriasis within the specified time period prior to initial dosing or planned for the duration of the trial (see Appendix 2: Concomitant medications during the trial);
  8. Participants who are participating in another interventional clinical trial or whose last use of another investigational drug is less than 5 half-lives prior to the first dosing of the investigational drug;
  9. any history of infection or recurrent infection requiring systemic antibiotic treatment within 2 weeks prior to first dosing, or serious infection requiring hospitalization or intravenous antibiotic treatment within 8 weeks prior to first dosing (e.g., pneumonia, cellulitis, bone or joint infection, etc.); Recurrent, chronic, or other active infection at the time of initial dosing, if the investigator determines that participation in the study increases participants' risk;
  10. Use of a suppressant of liver metabolic enzyme, or use of any medication, including prescription, over-the-counter, and herbal oral or topical drugs, other than vitamins and/or Paracetamol, within 2 weeks prior to initial administration;
  11. Participants who have received, or plan to receive, a live or attenuated vaccine within 4 weeks prior to initial administration;
  12. Abnormal laboratory test results during screening, including:

    1. (ALT), aspartate aminotransferase (AST) or basic phosphoric acid

      Enzyme (ALP) > 2.5 × (ULN);

    2. Serum creatinine > 1.5×ULN, or \< 50 mL/min.
  13. surface antigen (HBsAg) positive or hepatitis B core antibody (HBcAb) positive, and hepatitis B virus deoxyribonucleic acid (HBV-DNA) positive; Or virus (HCV) antibody positive and HCV-RNA positive; Or positive for , Treponema Pallidum-Antibody (TP-Ab) (Rapid Plasma Reagin, TP-AB) RPR] or Toluidine Red Unheated Serum Test (except for negative Toluidine Red Unheated Serum Test, TRUST);
  14. The presence of decompensated cardiac insufficiency (New York Heart Disease Assocation () class III or IV) within 6 months prior to screening; History of unstable angina pectoris, myocardial infarction, coronary artery bypass grafting or coronary stent implantation; There are severe arrhythmias that require medication or cardiac assistance, such as degree II type 2 or degree III atrioventricular block, long , or long QT block. QT syndrome or Fridericia Corrected QT Interval (QTcF) abnormality (male > 470 ms female > 480 ms) corrected according to the Fridericia formula and assessed by the investigator as unsuitable for participation in this clinical trial; Hospitalization due to Cardiovascular (CV) events, CV disease or CV surgery; Peripheral artery disease diagnosed by angiography with stroke (ischemic or hemorrhagic, including ) should be excluded;
  15. Known malignant tumors or history of malignant tumors (excluding clinically cured skin basal cell carcinoma, skin squamous cell carcinoma, cervical carcinoma in situ);
  16. Patients with psychoneuro-related diseases or history (such as depression, epilepsy), which affect medication compliance or the researcher's clinical judgment of suicide risk;
  17. Pregnant or lactating women, female subjects or male subjects' partners planning to become pregnant (within 6 months after signing the to the last administration of the study drug);
  18. Other conditions deemed unsuitable for participation in this study by the investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Placebo comparator
    QY101 placebo ointment

    40 subjects use QY101 placebo ointment twice daily for 12 weeks

    Drug: QY101Placebo/QY101 ointment

  • Experimental
    0.3% QY101 ointment

    60 subjects use QY101 placebo ointment twice daily for 12 weeks

    Drug: QY101Placebo/QY101 ointment

  • Experimental
    1.0 % QY101 ointment

    60 subjects use1.0 % QY101 ointment twice daily for 12 weeks

    Drug: QY101Placebo/QY101 ointment

Interventions

  • DrugQY101Placebo/QY101 ointment

    External use for BID

06

What researchers measure

Primary outcomes

  1. Physician Global Assessment(PGA)response

    At week 8, the proportion of subjects in each trial group who responded to the Physician Global Assessment (PGA) compared to the placebo group. The PGA response was defined as a PGA score of 0 (clear) or 1 (nearly clear) and an improvement of ≥ 2 points from baseline on the PGA scale.

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Feb 2024, 9 months after the start.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's planned 9 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Dec 14, 2023
StartActual
May 17, 2023
Primary completionEst.
Feb 29, 2024
CompletionEst.
Apr 30, 2024
Last update
Dec 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06170840
Lead sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Dec 14, 2023
Start date
May 17, 2023
Primary completion
Feb 29, 2024 (estimated)
Completion
Apr 30, 2024 (estimated)
Last update
Dec 19, 2023

Study contacts

Xiaoyong Man, Doctor
Contact
manxy@zju.edu.cn
+86 1360051 6219

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion